Is monthly retreatment with intravitreal bevacizumab (Avastin^®) necessary in neovascular age-related macular degeneration?

Nicola G GhaziDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USACorrespondence[email protected]

Tyler Q KirkDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USA

Robert M KnapeDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USA

James S TiedemanDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USA

Brian P ConwayDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USA

Pages 307-314 | Published online: 08 Apr 2010

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GragoudasESAdamisAPCunninghamETJrVEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group, Pegaptanib for neovascular age-related macular degenerationN Engl J Med20043512805281615625332
PubMed Web of Science ®Google Scholar
HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
PubMed Web of Science ®Google Scholar
MichelsSRosenfeldPJPuliafitoCASystemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical studyOphthalmology20051121035104715936441
PubMed Web of Science ®Google Scholar
van WijngaardenPCosterDJWilliamsKAInhibitors of ocular neovascularization promises and potential problemsJAMA20052931509151315784876
PubMed Web of Science ®Google Scholar
BakriSJCameronJDMcCannelCAAbsence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit modelAm J Ophthalmol200614216216416815270
PubMed Web of Science ®Google Scholar
LuthraSNarayananRMarquesLEEvaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cellsRetina20062651251816770256
PubMed Web of Science ®Google Scholar
ShaharJAveryRLHeilweilGElectrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)Retina20062626226916508424
PubMed Web of Science ®Google Scholar
ManzanoRPPeymanGAKhanPKivilcimMTesting intravitreal toxicity of bevacizumab (Avastin)Retina20062625726116508423
PubMed Web of Science ®Google Scholar
AveryRLPieramiciDJRabenaMDIntravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationOphthalmology2006113363372e516458968
PubMed Web of Science ®Google Scholar
MaturiRKBleauLAWilsonDLElectrophysiologic findings after intravitreal bevacizumab (Avastin) treatmentRetina20062627027416508425
PubMed Web of Science ®Google Scholar
SpaideRFLaudKFineHFIntravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degenerationRetina20062638339016603955
PubMed Web of Science ®Google Scholar
RichRMRosenfeldPJPuliafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina20062649551116770255
PubMed Web of Science ®Google Scholar
BashshurZFBazarbachiASchakalAIntravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degenerationAm J Ophthalmol20061421916815245
PubMed Web of Science ®Google Scholar
YamamotoIRogersAHReichelEIntravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopiaBr J Ophthalmol20079115716016870653
PubMed Web of Science ®Google Scholar
HeierJSAntoszykANPavanPRRanibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose studyOphthalmology20061134642e1e4
Web of Science ®Google Scholar
MordentiJCuthbertsonRAFerraraNComparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administrationToxicol Pathol19992753654410528633
PubMed Web of Science ®Google Scholar
MordentiJThomsenKLickoVIntraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulationToxicol Sci19995210110610568703
PubMed Web of Science ®Google Scholar
FungAERosenfeldPJReichelEThe international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwideBr J Ophthalmol200690111344134916854824
PubMed Web of Science ®Google Scholar
KlettnerAKKruseMLMeyerTDifferent properties of VEGFantagonists: bevacizumab but not ranibizumab accumulates in RPE cellsGraefes Arch Clin Exp Ophthalmol2009247121601160819597740
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Is monthly retreatment with intravitreal bevacizumab (Avastin^®) necessary in neovascular age-related macular degeneration?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Is monthly retreatment with intravitreal bevacizumab (Avastin^®) necessary in neovascular age-related macular degeneration?